Insmed Inc Stock Price, News & Analysis

Insmed will host a commercial webinar on June 4, 2024, at 8:00 a.m. ET to discuss the market outlook for its key programs: ARIKAYCE®, brensocatib, and TPIP. Shareholders and interested parties can join the conference call by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) with access code 7504027. The call will also be webcast on Insmed's website and a replay will be available until July 4, 2024. The archived webcast will be accessible for 90 days in the Investor Relations section on the company’s site.

Insmed announced the pricing of a public offering of 12,621,359 shares of common stock at $51.50 per share, targeting $650 million in gross proceeds. An additional 1,893,203 shares are available to underwriters within a 30-day option. The funds will support research and development, commercialization of brensocatib, and other corporate purposes. Closing is expected on May 31, 2024, subject to customary conditions. Goldman Sachs, Leerink Partners, and J.P. Morgan lead the offering.

Insmed (Nasdaq: INSM), a biopharmaceutical company, has announced a proposed public offering of $500 million worth of its common stock. The company intends to provide underwriters with a 30-day option to purchase up to an additional 15% of the shares. All shares will be sold by Insmed, with Goldman Sachs & Co. and Leerink Partners acting as joint book-running managers. The offering is dependent on market conditions and other factors, and there is no assurance of its completion or terms. The public offering will be made through Insmed's shelf registration statement filed with the SEC, which became effective on May 19, 2023. Preliminary prospectus supplements will be available on the SEC's website in due course.

Insmed announced positive topline results from the ASPEN Phase 3 study of brensocatib in patients with non-cystic fibrosis bronchiectasis. The study met its primary endpoint, showing statistically significant reductions in pulmonary exacerbations (PEs) for both dosage strengths versus placebo. Secondary endpoints also showed significant improvements. Brensocatib was well-tolerated, and Insmed plans to file a New Drug Application with the FDA in Q4 2024, aiming for a mid-2025 U.S. launch. If approved, brensocatib would be the first treatment for bronchiectasis and the first dipeptidyl peptidase 1 (DPP1) inhibitor. Detailed results will be presented at an upcoming medical meeting.

Study findings included a 21.1% reduction in annualized rate of PEs for the 10 mg dose and 19.4% for the 25 mg dose. Secondary outcomes included an 18.7% and 17.5% prolongation in time to first PE for the respective doses. Brensocatib also showed improvements in forced expiratory volume and quality of life scores. The study engaged over 460 sites globally. Insmed will host an investor call on May 28, 2024, to discuss the results.

Insmed will host an investor call on May 28, 2024, at 8:00 am ET to discuss the topline results from the Phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis. The company will release the results at 6:30 am ET, prior to the call. The ASPEN study is a global, randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of brensocatib. The conference call can be accessed via phone or webcast, with a replay available until June 27, 2024.

Insmed presented positive data from its Phase 3 ARISE study of ARIKAYCE® (amikacin liposome inhalation suspension) at the American Thoracic Society 2024 International Conference. The study evaluated patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC). ARIKAYCE combined with a macrolide-based regimen showed significantly greater improvements in respiratory symptoms and higher rates of culture conversion compared to the macrolide regimen alone. Quality of Life-Bronchiectasis (QOL-B) scores improved through Month 7 for ARIKAYCE patients, whereas improvements plateaued or worsened for the comparator group after Month 3. No patients developed resistance to ARIKAYCE or macrolides. Adverse event rates were higher in the ARIKAYCE arm but were consistent with expected safety profiles.

Insmed Incorporated reported total revenue of $75.5 million for the first quarter of 2024, showing 16% growth over the same period in 2023. The company highlighted positive safety and tolerability data from TPIP studies and encouraging results from PAH trials. They reiterated their 2024 revenue guidance of $340-360 million for global ARIKAYCE. Insmed continues to focus on commercial expansion, R&D for brensocatib and TPIP, and early-stage research programs.

Insmed Incorporated (Nasdaq:INSM) will present at the BofA Securities Health Care Conference 2024, aiming to transform the lives of patients with serious and rare diseases. The fireside chat will take place on May 14, 2024, at 2:20 p.m. PT (5:20 p.m. ET) in Las Vegas, NV. The webcast will be accessible on the company's investor relations website for 30 days post-event.

Insmed Incorporated (INSM) granted inducement awards to 63 new employees as a material inducement to their employment. The employees received options to purchase 410,300 shares of Insmed common stock at an exercise price of $25.59 per share. The options have a 10-year term and a four-year vesting schedule.